GLP-1 agonists, a class of medication typically used ... and the toxic effects of Alzheimer’s biomarkers amyloid-beta and tau, and improving how the brain’s nerve cells communicate.” ...

“As the scientific community deservingly celebrates GLP-1 agonists and their impact ... pathological proteins beta-amyloid and alpha-synuclein, respectively, interact with certain receptors ...

Glucagon-like peptide-1 (GLP-1) agonist drugs have been prescribed for ... glucagon binds to a specific receptor on the surface of beta cells in the pancreas, causing them to release insulin ...

This is in regard to the development of LPA1R agonist LTSE-2578 for the treatment of patients with IPF as well. A phase 1 randomized study for this program was initiated in June 2024 and is ongoing.

Columnist Jen Cueva talks with her friend Lynda Pinto, who has PH, about Lynda's experience with GLP-1 agonist medications.

New research presented May 17 at the American Psychiatric Association's Annual Meeting shows that GLP-1 receptor agonists may ...

The two main beta receptors that are targeted by beta blockers are the beta 1 receptor and the beta 2 receptor. A large number of beta 1 receptors are present on the heart and kidney cells ...

Diabetic patients treated with GLP-1 receptor agonists (GLP-1RAs ... and the need for first-line treatments for glaucoma (including beta-blockers, prostaglandin analogs, brimonidine, brinzolamide ...

GLP-1, and glucagon Receptors, improves markers of pancreatic beta-cell function and insulin sensitivity" ADA 2024; 266-OR.

It may also hamper their survival. To investigate whether DYRK1A inhibitor harmine and the GLP-1 agonist exendin-4 support beta cell health, the scientists turned to a mouse model. They ...